Florida’s XYMOGEN, a family-owned health science company headquartered in Orlando, recently earned prestigious qualification from Australia’s Therapeutic Goods Administration (TGA), the nation’s corresponding version of the U.S. Food and Drug Administration (FDA), having met rigorous procedural standards.
"This is an important milestone for us and validates our focus and commitment to the manufacture and quality of dietary supplements," Brian Blackburn, XYMOGEN founder and CEO, said. "It matters to us that we adhere to and uphold the highest manufacturing standards to ensure the highest level of quality. It's our culture and it's why our clients trust XYMOGEN."
The firm was required to demonstrate the highest possible level of adherence to manufacturing and quality parameters. The company took two years to work toward TGA eligibility, noting that TGA’s standards are even stricter than those of the FDA.
TGA certification is acknowledged worldwide as implementing one of the world's most rigorous GMP (good manufacturing practices) audit processes in the dietary supplement industry, with standards closely matching pharmaceutical-level GMP requirements.
Blackburn noted that XYMOGEN’s achievement was made possible by shared collaboration from all of the company’s departments.
The “nutraceutical” company has introduced many products into the functional medicine community in its 25 years. XYMOGEN was recognized in 2015 by Inc. magazine as one of America’s top 5000 fastest growing, best-run, original and inspiring private companies.
6900 Kingspointe Parkway
Orlando, FL - 32819